These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33127761)

  • 1. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
    Biasci D; Smoragiewicz M; Connell CM; Wang Z; Gao Y; Thaventhiran JED; Basu B; Magiera L; Johnson TI; Bax L; Gopinathan A; Isherwood C; Gallagher FA; Pawula M; Hudecova I; Gale D; Rosenfeld N; Barmpounakis P; Popa EC; Brais R; Godfrey E; Mir F; Richards FM; Fearon DT; Janowitz T; Jodrell DI
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28960-28970. PubMed ID: 33127761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Fearon DT; Janowitz T
    Br J Cancer; 2021 Jul; 125(2):149-151. PubMed ID: 33772153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CXCR4-dependent immunosuppressive Ly6C
    Jung K; Heishi T; Incio J; Huang Y; Beech EY; Pinter M; Ho WW; Kawaguchi K; Rahbari NN; Chung E; Kim JK; Clark JW; Willett CG; Yun SH; Luster AD; Padera TP; Jain RK; Fukumura D
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10455-10460. PubMed ID: 28900008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
    Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
    Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
    Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
    Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
    Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells.
    Heinrich EL; Lee W; Lu J; Lowy AM; Kim J
    J Transl Med; 2012 Apr; 10():68. PubMed ID: 22472349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of soluble HLA-G mediated immune modulation: downregulation of T cell chemokine receptor expression and impairment of chemotaxis.
    Morandi F; Ferretti E; Bocca P; Prigione I; Raffaghello L; Pistoia V
    PLoS One; 2010 Jul; 5(7):e11763. PubMed ID: 20668702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
    Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
    Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
    [No Abstract]   [Full Text] [Related]  

  • 13. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
    Daniel SK; Seo YD; Pillarisetty VG
    Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
    Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
    World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer.
    Xu Q; Wang Z; Chen X; Duan W; Lei J; Zong L; Li X; Sheng L; Ma J; Han L; Li W; Zhang L; Guo K; Ma Z; Wu Z; Wu E; Ma Q
    Oncotarget; 2015 Mar; 6(7):4717-32. PubMed ID: 25605248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.
    D'Alterio C; Giardino A; Scognamiglio G; Butturini G; Portella L; Guardascione G; Frigerio I; Montella M; Gobbo S; Martignoni G; Napolitano V; De Vita F; Tatangelo F; Franco R; Scala S
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
    Khare T; Bissonnette M; Khare S
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of CXCL12-CXCR4 and its association with angiogenesis in pancreatic cancer].
    Niu ZX; Fei LM; Wang CL
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):286-7. PubMed ID: 19615285
    [No Abstract]   [Full Text] [Related]  

  • 20. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
    Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.